Innovation Pharmaceuticals Inc (IPIX)

[Cognition]

Remdesivir was just throwing right jabs at the VID. Brilacidin comes in with the left hook and the uppercut for the victory!
“Brilacidin appears to have primarily an extracellular mechanism of action, by disrupting viral integrity and blocking viral entry. In contrast, Remdesivir—currently authorized by the FDA for emergency use against COVID-19—has an intracellular mechanism of action, affecting viral replication post-infection. Exhibiting different but synergistic antiviral properties, these two drugs may be an especially potent drug combination in treating COVID-19”.

Combo trial coming very soon IMO. All IPIX will need to do is supply the B.